LMH STRATEGIC SOLUTIONS

Lobbying for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Biopharmaceutical industry trade association.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $30,000.00 income · posted Apr 17, 2026

Bills named in this filing 3

HR 2213
Medical Supply Chain Resiliency Act
HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
S 832
EPIC Act of 2025

Lobbying activity 2

Pharmacy

Pharmaceutical Supply Chain. H.R.2213: Medical Supply Chain Resiliency Act. Issues related to the 340(b) program. H.R.1492/S.832: EPIC Act of 2025.

Trade (domestic/foreign)

Issues related to USTR/trade.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.